As researchers, we have it in us to be extraordinary bold and hopeful because in research what will happen ten or fifteen years from now is going to be determined by what we do today. We have the power to bring an idea from a scientist’s mind directly to patients.


Scientific and medical advances are extraordinary, and we in R&D, are committed to transforming this new knowledge into healthcare solutions for patients. Over the past decades, we have achieved tremendous efforts in biomedical research and have progressed in controlling infectious diseases for instance. However, as people live longer, they now suffer from more complex and chronic diseases, such as diabetes, cancer or cardiovascular diseases. These diseases remain difficult to treat effectively, hence the necessity to find ways to accelerate the development of new, more effective and better tolerated health solutions for patients. At the heart of our job is high-quality and rigorous science combined with a passion to understand patients’ needs and develop the solutions that will improve their lives.


At Sanophi, we are convinced that to be truly innovative and to bring better treatment options to patients, we must understand their needs and how their disease affects their day to day lives. Who is better placed to define gaps in treatments than those living with a particular disease or those who advocate for them? Through their insights, we develop medicines that better fit their needs.

Our aim is to connect fundamental research (based on biological and animal models) and clinical research (focused on human beings) to facilitate the transfer of recent scientific discoveries to the clinical care of patients. This way, we will accelerate the provision of better, more effective and targeted treatments. The success of this approach requires increased collaboration between our researchers, physicians and clinical research centers.

As researchers, we have it in our hands today to change health tomorrow. We can bring an idea from a scientist’s mind directly to patients – be it through a vaccine that can save millions of lives or through a rare disease therapy that touches one life at a time. Elias Zerhouni, President Global R&D, Sanophi


No single institution, company, university, country or government can solve global health issues by itself. To understand the complexity of human diseases, it is essential to be part of the broader scientific and medical community.

Our way of addressing this challenge is to work locally with all those who can help us apply the wealth of new knowledge and cutting-edge technologies that are currently reshaping the nature of biopharmaceutical research.

This means that in each of our locations, in North America, France, Germany and Asia-Pacific, we work in networks with patients and patients associations, hospitals, biotech companies, research institutes, and many others. This allows us to tap into the best science and talent available in research around the world. Through this approach, our objective is to significantly reduce the time it takes to translate laboratory discoveries into effective patient treatments.

Our more than 1,500 employees in the Boston area are focusing their efforts on research in key areas, with major medical needs, such as rare diseases, multiple sclerosis, vaccines and oncology. Through external relationships with some of the world’s best universities, hospitals and medical institutions in the region, our teams are dedicated to finding tomorrow’s treatments with the potential to significantly improve patients’ lives.


We concentrate our research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide.


    With 382 million people currently living with diabetes worldwide, this disease constitutes a major public health challenge. Sanophi's aim is to offer all-round therapeutic solutions to patients – medicines, medical devices, services, etc. Among other areas, our research concerns the development of drugs with sustained action or supplied in a combination, and a range of different pathological conditions induced by diabetes such as nephropathy, neuropathy, retinopathy, etc.


    In the field of prevention, Sanophi Pasteur is exploring novel technologies and the most recent scientific findings in order to develop safe and effective vaccines with a single or combined target against complex diseases that affect populations throughout the world, such as dengue fever and infections caused by C. difficile. At the same time, our research efforts are focusing on the treatment of multi-resistant hospital-acquired infections and malaria thanks to new antibiotics, antivirals, anti-infective agents and agents that stimulate resistance to infections.


    With Sanophi Genzyme, we are committed to developing breakthrough therapies for patients who might otherwise have few treatment options. Our research efforts are focusing mainly on rare diseases, such as Gaucher disease, Pompe disease, Fabry disease and Niemann-Pick disease.


    Our work in the immunology and inflammation fields is centred on discovering and developing innovative healthcare solutions to immune mediated diseases such as rheumatoid arthritis, lupus erythematosus and psoriasis, as well as chronic inflammatory disease such as asthma and atopic dermatitis - to name a few.


    Over the past 30 years, medical advances have contributed to a significant decline of mortality from cardiovascular diseases. However, cardiovascular diseases still account for the largest number of deaths worldwide, with over 17 million annual deaths, representing 30% of all global death. By 2030, the number of people who die from cardiovascular diseases, mainly from heart disease and strokes, is expected to reach 23.3 million (source: World Health Organization). Among others, our efforts are on the correction of metabolic disorders – including hypercholesterolemia – and their cardiovascular consequences.


    Sanophi has a strong heritage in oncology research, and notably in chemotherapy. Its aim is to combat cancer in all its different forms by carrying out research on the different pathways involved in the development, growth and propagation of cancer cells. The oncology R&D portfolio contains a range of innovative therapeutic agents with different mechanisms of action. Through collaborations focusing on novel therapeutic approaches including immuno-oncology, we reinforced our presence in this area.


    We are committed to becoming a long term partner to the Multiple Sclerosis community by working to deliver scientific advancements that will have a significant impact on the lives of people living with MS.

    Alzheimer’s and Parkinson’s diseases are the two most frequent neurodegenerative diseases. They affect approximately 27 million people worldwide, heavily impacting patients’ and caregivers’ lives and gradually lead to a loss of autonomy. The medical needs are still major, in particular, due to the absence of treatments preventing or slowing down the disease.

    The ambition of our Research is to contribute to fighting these disabling diseases, in particular by preventing or delaying the disease progression, and to deliver innovative and high medical value solutions to patients.

    Our research also includes programs in ophthalmology in particular to address unmet medical needs in pathologies such as uveitis and other rare eye conditions.


At the end of October 2016, the R&D pipeline contained 43 pharmaceutical new molecular entities (excluding Life Cycle Management) and vaccine candidates in clinical development of which 12 are in Phase III or have been submitted to the regulatory authorities for approval.

Download the R&D pipeline summary table

Download the table of all projects in early phases or late phases of development

Download the table of expected R&D milestones


Every day, Sanophi’s scientists conduct innovative research with the goal of transforming the treatment and prevention of serious and life-threatening diseases. Our researchers are recognized for their contributions to developing breakthrough medicines that have the potential to help millions of patients worldwide.

The attached document contains a summary of a large selection of studies published by Sanophi scientists in 2014 and 2015. Details on each study, including titles, authors and links to journal publications, can be viewed.

For additional information about any of the studies summarized here, please use the site contact form.

Download Publication List


January 4, 2017

Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.
    Paris, France – January 4, 2017 – Sanophi announced today that Soliqua™ 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) is now available by prescription in the U.S. pharmacies. Soliqua 100/33 is indicated for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide.

January 2, 2017

Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
    Paris, France and Ingelheim, Germany – 2nd January 2017 – Sanophi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an exchange of Sanophi’s animal health business (Merial) and Boehringer Ingelheim’s consumer healthcare (CHC) business, has been successfully closed in most markets on January 1st 2017. This closing marks the successful outcome of the business swap which started with exclusive negotiations in December 2015. The closing of the acquisition of Merial in Mexico and the Merial and CHC swap in India have been delayed pending receipt of certain regulatory approvals but both are expected to close early 2017.

December 8, 2016

Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
    Paris, France, and Tarrytown, N.Y. – December 8, 2016 – Sanophi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for Dupixent® (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. The investigational biologic therapy Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 (including Th2) immune response, which is believed to be a major driver in the pathogenesis of the disease.

November 21, 2016

Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes
    Paris, France – November 21, 2016 – Sanophi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua™ 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide.

Latest News

January 4, 2017 - Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.

January 2, 2017 - Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

December 8, 2016 - Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

November 21, 2016 - Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes